Wuhan Institute of Biological Products Co Ltd has prepared the first batch of its quadrivalent influenza vaccines (split virion, inactivated) to the UAE for shipment. [Photo/sinopharm.com]

Wuhan Institute of Biological Products Co Ltd under China National Biotec Group Co Ltd (CNBG), a member company of China National Pharmaceutical Group Co Ltd (Sinopharm), recently shipped the first batch of its quadrivalent influenza vaccines (split virion, inactivated) to the United Arab Emirates (UAE). 

This is the first time this vaccine has been transported to the UAE following its export to Kenya, indicating international recognition of its safety and efficacy.

Staff workers of CNBG ship the first batch of its quadrivalent influenza vaccines (split virion, inactivated) to the UAE. [Photo/sinopharm.com] 

This quadrivalent influenza vaccine received its drug registration certificate from the UAE’s Ministry of Health and Prevention on Jan 3. Subsequently, on May 3, it secured a procurement order from the country for the year 2024. 

This export initiative is a concrete practice by CNBG to implement the concept of building a global community of health for all. It also represents a proactive step taken by Wuhan Institute of Biological Products Co Ltd to steadily advance its internationalization strategy.

A file photo of the quadrivalent influenza vaccine (split virion, inactivated) developed by CNBG’s Wuhan Institute of Biological Products Co Ltd [Photo/sinopharm.com] 

Looking ahead, Sinopharm aims to serve national strategies effectively in the healthcare sector. It seeks to leverage technological innovation, industrial control capabilities and safety assurances to promote self-reliance in technology, accelerate the development of strategic emerging and future industries, and drive the advancement of new quality productive forces in the biopharmaceutical field.